Advanced genetic and reproductive technologies in salmon aquaculture — including growth hormone transgenic salmon and triploid sterile fish — raise distinct welfare questions that require evidence-based assessment.
Advanced genetic and reproductive technologies in salmon farming require welfare assessment that goes beyond conventional production concerns. Triploid salmon, produced through chromosome manipulation, show elevated rates of skeletal deformity and cataract development compared to diploid salmon — welfare costs that arise directly from the production method rather than environmental factors. If triploid welfare is compromised relative to diploids, this must be weighed against the environmental containment benefits of sterility. Growth hormone transgenic salmon that grow year-round may experience metabolic demands that create physiological stress not present in seasonal diploid growth patterns. These welfare questions deserve rigorous research and transparent regulatory assessment rather than dismissal or assumption of equivalence to conventional production. The scale of potential deployment means that welfare findings at the individual level aggregate to significance across millions of fish.